News

APRINOIA Therapeutics Inc. Launches a New Contract Service to Measure High-Molecular-Weight Oligomer Tau Species Using High-Sensitive ELISA System Tokyo, Japan, May 7, 2025 – APRINOIA Therapeutics Inc. (“APRINOIA”), a clinical-stage biopharmaceutical company, is pleased to announce a new service for HMWoTau measurements for research institutions and companies engaged in pathophysiological research and drug/diagnostics development targeting tau proteins. This service is based on our research...

APRINOIA Therapeutics Reported a Novel Oligomer Tau Assay System with APNmAb005 Antibody, Successfully Detected the Target Molecule of Oligomer Tau Species and Elucidated the Increases Depending on Disease Progression of Alzheimer’s Disease Tokyo, Japan – December 10, 2024 – APRINOIA Therapeutics has developed a novel enzyme-linked immunosorbent assay (ELISA) that employs its proprietary monoclonal antibody APNmAb005, which has high selectivity and sensitivity to its target molecule high-molecular-weight...

APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 for the Diagnosis of Progressive Supranuclear Palsy Fast Track Designation follows announcement in January 2024 that the U.S. Food and Drug Administration (FDA) granted a “Study May Proceed” letter for APRINOIA’s planned Phase 3 study of APN-1607 (florzolotau (18F)) in the U.S.,U.K., Europe and Asia CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) — APRINOIA Therapeutics (“APRINOIA” or the “Company”), a clinical-stage...

APRINOIA Therapeutics Inc. receives “Study May Proceed” letter from FDA for a Phase 3 study of APN-1607 (florzolotau) for the diagnosis of Progressive Supranuclear Palsy Cambridge, MA, January 3, 2024 — APRINOIA Therapeutics Inc. (“APRINOIA” or the “Company”) is pleased to announce that on December 8, 2023, the United States Food and Drug Administration (“FDA”) has issued a “Study May Proceed” letter for APRINOIA’s newly filed investigational new drug application for the clinical investigation...

APRINOIA Therapeutics Announces Strategic Investment From the Alzheimer’s Drug Discovery Foundation (ADDF) Investment Supports APRINOIA’s Effort to Bring Precision Medicine to Neuroscience, Advancing APRINOIA’s Diagnostic and Therapeutic Pipelines. Funding Supports APRINOIA’s Goal to Bring a Central Nervous System (CNS) Protein Degrader Candidate to Investigational New Drug (IND)-Enabling Study. Proceeds also Intended to Advance APRINOIA’s Late-Stage Tau Positron Emission Tomography (PET) to...

APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer Dr. Shearman, a pharma and biotech industry executive with an extensive track record of achievements in drug discovery and development, will lead the strategy and execution of the company’s clinical therapeutic and diagnostic programs August 28, 2023 11:00 ET APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for the treatment...

APRINOIA Therapeutics Announces Mutual Termination of Business Combination Agreement with ROSS Acquisition Corp II CAMBRIDGE, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) — APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for the treatment of neurodegenerative diseases such as Alzheimer’s Disease (“AD”) and Progressive Supranuclear Palsy (“PSP”), announced a mutual termination of its previously announced...

APRINOIA Therapeutics and ROSS Acquisition Corp II Announce Business Combination Agreement to Create Publicly Listed Company Focused on Neurodegenerative Diseases ROSS SPAC will issue $280 million of stock for APRINOIA Therapeutics Precision Neurology Company Focused on Developing a Pipeline of Highly Specific Central Nervous System (“CNS”) Diagnostics and Therapeutics, including CNS Protein Degraders Anticipated Proceeds From Transaction Expected to Finance Several Key Therapeutic and Diagnostic...

APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial BOSTON, April 11, 2022 — APRINOIA Therapeutics announces today that the U.S. Food and Drug Administration (FDA) has granted a may proceed authorization for its novel therapeutic anti-tau monoclonal antibody, APNmAb005, allowing the company to test and evaluate its safety in healthy subjects in a phase 1 single ascending dose study. APNmAb005 is a unique antibody that recognizes a conformation-dependent...

APRINOIA Therapeutics has completed Series C financing with a total amount of $40 million USD in 2021. The financing was led by Yantai Dongcheng Pharmaceutical Group and syndicated by current shareholders KTB Network, IMM, and TaiAn Technologies and several new investors, including Harvest Capital, a fund established by the Management Committee of Suzhou Industrial Park (SIP).

Insilico Medicine is pleased to announce that it has entered into a research collaboration with APRINOIA Therapeutics to utilize Insilico’s novel generative artificial intelligence (AI) technology to accelerate the discovery of next generation compounds targeting abnormal proteins in brain associated with neurodegenerative diseases.

APRINOIA Therapeutics Inc. today announced that they had executed a worldwide non-exclusive licensing agreement for Biogen Inc. (Nasdaq: BIIB) to access APRINOIA’s positron emission tomography (PET) imaging tracer, 18F-APN-1607, for neurodegenerative diseases. This is an extension of a collaboration between APRINOIA and Biogen to discover novel PET imaging tracers for visualization and quantification of abnormal tau protein accumulation in the brain.

APRINOIA Therapeutics announced today that China National Medical Products Administration (NMPA) had approved to initiate Phase 3 clinical trial to evaluate APRINOIA’s positron emission tomography (PET) imaging tracer, 18F-APN-1607, targeting abnormal tau protein aggregates in brains of patients of cognitive impairment.

APRINOIA Therapeutics, Inc. announced today that it has initiated a Phase 2 multicenter, multinational study of 18F-APN-1607 in the US for its lead tau positron emission tomography (PET) tracer in Alzheimer's Disease (AD). The study (NCT number: NCT04141150) will compare tau deposition patterns in patients with mild cognitive impairment due to AD and dementia due to AD with patterns in healthy older adults.

APRINOIA Therapeutics has initiated a collaboration with Keio University in Tokyo, Japan to profile patients with dementia using APRINOIA’s tau PET imaging tracer, 18F-APN-1607 (PM-PBB3). The collaboration is a part of the EKID (Eisai-Keio Innovation Laboratory for Dementia) study conducted by Keio University and Eisai Co. Ltd., which is supported by a research grant (No. JP17pc0101006) from AMED (Japan Agency for Medical Research and Development). APRINOIA is grateful for the opportunity to contribute...

APRINOIA Therapeutics announces today that it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) for the development of alpha-synuclein PET imaging tracers.

APRINOIA Therapeutics announced today that it has entered into a non-exclusive licensing agreement with Celgene Corporation. The agreement authorizes Celgene to use APN-1607, a novel investigational [18F]-labeled positron emission tomography (PET) imaging tracer, to support patient selection and efficacy evaluation in its global clinical trials.

​Aprinoia Therapeutics Inc. is developing a pipeline targeting tauopathies that includes diagnostic imaging tracers, mAbs specific to pathologic tau and small molecules that bind to tau rather than dissociate tau aggregates. “We are going to develop imaging biomarkers for all the therapeutic targets first to see those targets, and then find therapies,” CEO Ming-Kuei Jang told BioCentury.

APRINOIA has completed its US$11.1 million Series B round. The Series B round was led by KTB Network (Korea) and DCI Partners (Japan), along with participations from ShangPharma Investment Group (China) and TaiAn Technologies (Taiwan). The proceeds of the funding will be used to finance preclinical and clinical development for APRINOIA’s tau centric programs.